[HTML][HTML] Development of second-generation VEGFR tyrosine kinase inhibitors: current status
P Bhargava, MO Robinson - Current oncology reports, 2011 - Springer
The vascular endothelial growth factor (VEGF) signaling pathway appears to be the
dominant pathway involved in tumor angiogenesis, providing a rationale for targeting the …
dominant pathway involved in tumor angiogenesis, providing a rationale for targeting the …
Biology and clinical development of vascular endothelial growth factor–targeted therapy in renal cell carcinoma
BI Rini, EJ Small - Journal of Clinical Oncology, 2005 - ascopubs.org
Purpose To review the biology of renal cell carcinoma (RCC) leading to vascular endothelial
growth factor (VEGF) overexpression and the clinical results of VEGF blockade in metastatic …
growth factor (VEGF) overexpression and the clinical results of VEGF blockade in metastatic …
Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor–signaling inhibitors
ES Robinson, EV Khankin, TK Choueiri… - …, 2010 - Am Heart Assoc
Therapies that target the vascular endothelial growth factor (VEGF) pathway cause
hypertension, but the mechanism remains unknown. This cross-sectional study tested the …
hypertension, but the mechanism remains unknown. This cross-sectional study tested the …
Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma
BI Rini, K Flaherty - Urologic Oncology: Seminars and Original …, 2008 - Elsevier
Vascular endothelial growth factor (VEGF) pathway activation leads to the angiogenic
phenotype of renal cell carcinoma (RCC). Several different strategies targeting various …
phenotype of renal cell carcinoma (RCC). Several different strategies targeting various …
Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review
The introduction of molecularly targeted anticancer therapies has brought the promise of
longer survival times for select patients with cancers previously considered untreatable …
longer survival times for select patients with cancers previously considered untreatable …
Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers
LS Rosen - Cancer control, 2002 - journals.sagepub.com
Angiogenesis is required for tumor growth and metastasis and, therefore, represents an
exciting target for cancer treatment. Angiogenesis is a complex process that is tightly …
exciting target for cancer treatment. Angiogenesis is a complex process that is tightly …
Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker
ES Robinson, EV Khankin, SA Karumanchi… - Seminars in …, 2010 - Elsevier
Drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are a
rapidly growing chemotherapy class for treatment of solid tumors. This targeted therapy is …
rapidly growing chemotherapy class for treatment of solid tumors. This targeted therapy is …
Biological mechanisms of bevacizumab-associated adverse events
GM Higa, J Abraham - Expert review of anticancer therapy, 2009 - Taylor & Francis
The perception that inhibition of cancer-associated angiogenesis would be an effective
treatment strategy was based on the fundamental difference in cell cycle activity between …
treatment strategy was based on the fundamental difference in cell cycle activity between …
An overview of small-molecule inhibitors of VEGFR signaling
SP Ivy, JY Wick, BM Kaufman - Nature reviews Clinical oncology, 2009 - nature.com
VEGFR inhibitors are in broad use for the treatment of metastatic renal-cell carcinoma,
gastrointestinal stromal tumors and hepatocellular carcinoma and in development in a …
gastrointestinal stromal tumors and hepatocellular carcinoma and in development in a …
[HTML][HTML] Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer
DH Roukos, A Tzakos, G Zografos - Expert Review of Anticancer …, 2009 - Taylor & Francis
Anti-angiogenic therapy in cancer has become very popular. Agents inhibiting new vessel
formation (angiogenesis) and blood supply can have anticancer effects. This idea …
formation (angiogenesis) and blood supply can have anticancer effects. This idea …